327 Drug Products to Enter China\’s 7th Round of Volume-based Procurement (VBP)
On July 13, the National Joint Drug Procurement Office announced the preliminary result for the bid of the 7th round of volume-based procurement (VBP). 327 products (61 drugs if differentiated by active ingredients) owned by 217 companies won the bid in the preliminary stage.
The bid-winning products cover 31 disease categories, including common and/or chronic diseases such as hypertension, diabetes, gastrointestinal disorders and severe diseases of lung/liver/kidney/colon cancer.
The bid-winning products\’ prices were reduced by 48% on average. In terms of kidney cancer drugs, the average price of Lenvatinib Mesilate Capsules was cut by 83.33% from 108 yuan/capsule to 18 yuan/capsule. Among drugs for treating high blood pressure, Nifexdipine Controlled-release Tablets\’ average price dropped by 58% and Metoprolol Succinate Sustained-Release Tablets\’ by 53%.
Of the 327 products, six are from international pharma companies and their VBP prices are listed below.
| Drug Product | Specification | Company | VBP Price |
| Oseltamivir Phosphate Capsules | 75mg*10 capsules per blister pack in each box | Hetero Labs Limited | 16.50 yuan/box |
| Iopamidol Injection | 100ml: 37g(I)*10 bottles in each box | Shanghai Bracco Sine Pharmaceutical Industry Co., Ltd. | 1,192.79 yuan/box |
| Ebastine Tablets | 10mg*10 tablets per blister pack in each box | Almirall, S.A. (Industrias Farmaceuticas Almirall, S.A.) | 3.49 yuan/box |
| Ezetimibe Tablets | 10mg*30 tablets in each box | Sandoz Inc. (Lek Pharmaceuticals d.d.) | 38.89 yuan/box |
| Micafungin Sodium for Injection | 50mg*1 bottle in each box | Astellas Pharma Europe B.V. (Astellas Pharma Tech Co., Ltd. Takaoka Plant) | 86.81 yuan/box |
| Tigecycline for Injection | 50mg*10 phials in each box | Pfizer Europe MA EEIG (Wyeth Lederle
S.r.l.) |
415.90 yuan/box |
Since 2018, China National Healthcare Security Administration (NHSA) has organized 7 rounds of VBPs which cover 294 drugs (differentiated by active ingredients). According to the estimation based on pre-VBP prices, drugs in the VBPs account for 35% of the chemical drugs and biological products procured by public medical institutions.
Reprinted from: ChemLinked
- [1] The National Joint Drug Procurement Office Announces the Preliminary Result of China’s 7th Round of VBP
